Tag Archive for: KlingBio

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies

/in

Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]

Read more

Optimum’s hot topic: Can we ‘bottle’ the remarkable biology of people who, against all odds, beat killer diseases?

/in

By Stephen Adams, Optimum Strategic Communications   Nature has been an inspiration behind the development of many drugs, starting with the humble aspirin, which was originally derived from willow bark.  But what if we could learn the secrets of what gives some people the incredible ability to overcome the most serious diseases?  What if we could […]

Read more

Weekly round-up: Catching up with the news after the busiest week in European biotech comes to a close

/in

Optimum Client’s Win Big at LSX European Lifestars Awards! Congratulations to Optimum’s clients – Asceneuron SA, Calliditas Therapeutics, DISCO Pharmaceuticals GmbH, Sofinnova Partners portfolio company Moon Surgical, Myricx Bio, and Novo Holdings, all of whom took home LSX European Lifestars awards! Plus, a special moment for Optimum’s Zoe Bolt who presented the award for Private […]

Read more